“…Several strategies have been employed to treat PDC-deficient patients, with variable and often limited success [18] , [19] , [20] , [21] . They include three major therapies (and often in some combination) [5] , [8] : (i) the use of a ketogenic diet to provide ketone bodies as an alternate fuel for brain metabolism (by-passing PDC reaction) [18] , [20] , [21] , [22] , [23] , [24] , [25] (ii) supplementation of high doses of thiamine, presumably to meet the increased Km requirement for thiamine pyrophosphate associated with some PDHA1 mutations and/or for enzyme stability [26] , [27] , [28] , [29] , [30] , [31] , and (iii) administration of dichloroacetate which is known to inhibit PDH kinases decreased blood cerebrospinal fluid lactate concentrations in a large number of PDC-deficient children [19] , [32] . Beneficial effect of phenylbutyrate on residual ‘active’ PDC activity was shown in skin fibroblast cell lines from PDC-deficient patients caring PDHA1 missense mutations [33] , [34] .…”